Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2024-10-09 DOI:10.1016/j.ygyno.2024.07.016

Mansoor Mirza , Sharad Ghamande , Lars Hanker , Destin Black , Nicoline Raascou-Jensen , Lucy Gilbert , Ana Oaknin , Angeles Alvarez Secord , Antonella Savarese , Robert Holloway , Rebecca Kristeleit , Joseph Buscema , Ingrid Boere , Sudarshan Sharma , Christine Gennigens , Prafull Ghatage , Kaitlin Yablonski , Shadi Stevens , Hanna Trukhan , Matthew Powell

引用次数: 0

查看原文本刊更多论文

ENGOT-EN6-NSGO/GOG-3031/RUBY试验中的原发性晚期或复发性子宫内膜癌患者接受多斯他利单抗加化疗后再接受多斯他利单抗加尼拉帕利的维持治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy